-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16, JSI Indah announced that it had received the "Clinical Trial Notice" approved and issued by the National Medical Products Administration, and its extracellular regulated kinase (ERK) inhibitor JSI-1187 capsule was approved for treatment A clinical trial of patients with advanced solid tumors with mutations in the MAPK signaling pathway
The ERK signaling pathway plays a key role in tumorigenesis and the regulation of key cell processes such as cell cycle progression, cell proliferation, migration, survival, differentiation, aging, metabolism, protein synthesis and angiogenesis
In addition, abnormal activation of the ERK pathway is also common in the secondary resistance of BRAF, MEK, KRAS, ALK, CDK4/6, TRKA and EGFR inhibitors that have been marketed
JSI-1187 is an oral, highly selective ERK1 and ERK2 small molecule kinase inhibitor independently developed by JSI.
Note: The original text has been deleted